Amedisys, Inc. v. JP Morgan Chase Manhattan Bank (In Re National Century Financial Enterprises, Inc.)

334 B.R. 907, 63 Fed. R. Serv. 3d 891, 2005 Bankr. LEXIS 2575, 2005 WL 3497805
CourtUnited States Bankruptcy Court, S.D. Ohio
DecidedDecember 22, 2005
DocketBankruptcy No. 02-65235. Adversary No. 02-2576
StatusPublished
Cited by3 cases

This text of 334 B.R. 907 (Amedisys, Inc. v. JP Morgan Chase Manhattan Bank (In Re National Century Financial Enterprises, Inc.)) is published on Counsel Stack Legal Research, covering United States Bankruptcy Court, S.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Amedisys, Inc. v. JP Morgan Chase Manhattan Bank (In Re National Century Financial Enterprises, Inc.), 334 B.R. 907, 63 Fed. R. Serv. 3d 891, 2005 Bankr. LEXIS 2575, 2005 WL 3497805 (Ohio 2005).

Opinion

MEMORANDUM OPINION AND ORDER ON JOINT MOTION TO STRIKE PORTIONS OF RECORD [ON APPEAL] DESIGNATED BY AMEDISYS, INC.

DONALD E. CALHOUN, JR., Bankruptcy Judge.

Defendants National Century Financial Enterprises, Inc. (“NCFE”) and JP Morgan Chase Manhattan Bank (“JP Morgan”) disagree with Plaintiffs, Amedisys, Inc. and its related entities (“Amedisys”), as to whether certain items should be included in the record on appeal. Amedisys has appealed the Court’s order granting partial summary judgment to the Defendants (“Order”). 1 See Amedisys, Inc. v. JP Morgan Chase Manhattan Bank (In re Nat’l Cent. Fin. Enters., Inc.), 310 B.R. 580, 584 (Bankr.S.D.Ohio 2004). Amedisys has designated items to be included in the record on appeal, which prompted NCFE and JP Morgan (collectively “Movants”) to request that some of the designated items be stricken.

The Court finds that it has the authority to adjudicate this dispute and determine the contents of the record on appeal. All the items that Movants seek to strike were never filed with or placed before the Court prior to its entry of the Order. Thus, the Court did not consider these items when it issued the Order. For this reason, the Court will grant Movants’ request to strike the contested items from the record on appeal.

I. Jurisdiction — Adversary Proceeding

The Court has jurisdiction over this adversary proceeding pursuant to 28 U.S.C. §§ 157 and 1334. This is a core proceeding pursuant to 28 U.S.C. § 157(b)(2).

II. Procedural Background

A. The Amedisys Adversary Proceeding

1. Pleadings

Amedisys commenced an action in the United States District Court for the Southern District of Ohio, Eastern Division against JP Morgan, NCFE, NPF VI, NPFS and Lance Poulsen on November 8, 2002. See Nat’l Cent. Fin. Enters., 310 B.R. at 584. Amedisys alleged that it submitted $7.3 million in receivables to *909 NPV VI under a sale and subservicing agreement (“Sale Agreement”) without receiving payment in return. Amedisys sought “the turnover of some $7.3 million which purportedly represented the proceeds of ‘non-purchased accounts receivable.’” Id.

Subsequently, NCFE, NPF VI and NPFS (collectively “Debtors”) each filed voluntary petitions for Chapter 11 bankruptcy relief on November 18, 2002; the Court eventually consolidated these cases for procedural purposes and administered them jointly. On December 19, 2002, the district court transferred this action to this Court. On February 21, 2003, Amedisys filed a first amended complaint naming JP Morgan and the Debtors as Defendants but removing JP Morgan as a Defendant to certain causes of action. Later, on January 16, 2004, Amedisys filed a second amended complaint (“Second Amended Complaint”), adding new counts and theories, but leaving the Defendants unchanged. See id. at 585.

The Second Amended Complaint alleged that NPF VI never purchased the receivables at issue and that the receivables still belong to Amedisys. Amedisys sought the return of $7.3 million (the purported value of those receivables) by asserting claims such as breach of fiduciary duty, breach of the Sale Agreement, express trust, constructive trust, resulting trust, turnover and conversion.

2. Order Granting Partial Summary Judgment

Debtors and JP Morgan filed motions for summary judgment, which this Court granted as to all claims but the one for breach of the Sale Agreement by the Debtors. Amedisys argued that it retained ownership of the receivables because NPF VI did not pay for them. The Court rejected the contention that NPF VI never purchased the receivables by concluding that Amedisys waived its right to receive the purchase price at the time the receivables were submitted to NPF VI.

The Court ... concludes that Amedisys waived its right to receive the purchase price of the accounts receivable submitted in October, 2002 pursuant to the Sale Agreement and thus is estopped from claiming that NPF VI did not purchase the accounts receivable. Overwhelming evidence submitted into the record shows that ... Amedisys sold the receivables to NCFE but did not request funding for the sale until the caprices of its own business cycle called for revenues.
... [A]ll of the evidence, including direct deposition testimony from Amedi-sys’ own CFO, shows that Amedisys did indeed sell its accounts receivable to NCFE, and they were of the “purchased accounts receivable” sort defined in the Sale Agreement.

Id. at 592.

In reaching this conclusion, the Court relied on statements made by Mr. Greg Browne, the CFO of Amedisys. Mr. Browne testified that Amedisys began “requesting] funding as we needed it” in April 2002. Id. He further testified that Amedisys sometimes “did not request the full amount” for the receivables, and he acknowledged that “no request was made” for funding during the first three weeks of October 2002. Id. at 593. Mr. Browne sent two emails (one to Roger Faulkenber-ry of NCFE and one to Huntington Bank) in which he stated that he considered the receivables at issue to be “purchased receivables.” This evidence led the Court to find that NPF VI had purchased the receivables from Amedisys even though it did not pay for them at the time. Id. at 595 (“In the present case, Amedisys, although well aware of its rights, voluntarily *910 and intentionally requested NCFE to withhold payments in anticipation of an acquisition.”)-

According to Amedisys, no such waiver occurred because the plain terms of the Sale Agreement provided for Amedisys to receive prompt payment for the receivables Amedisys submitted to NPF VI. Am-edisys argued that the terms of the Sale Agreement had not been properly modified or waived by a signed writing. See id. at 587 (noting that the terms of the Sale Agreement could not be modified unless the modification was “in writing and signed by each of the parties hereto.”). The Court rejected this contention by finding that emails and reconciliation reports' — exchanged between Amedisys and NPF VI on a weekly basis — satisfied the writing and signature requirements thereby properly modifying the terms of the Sale Agreement. See id. at 595-96 (citations omitted). Each week, Amedisys sent an email notifying NCFE how much funding it was requesting for that week. A reconciliation report was sent back to Am-edisys showing the amount requested. The Court determined that these emails and reports modified the Sale Agreement when Amedisys started requesting amounts other than the full purchase price of the receivables. See id.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
334 B.R. 907, 63 Fed. R. Serv. 3d 891, 2005 Bankr. LEXIS 2575, 2005 WL 3497805, Counsel Stack Legal Research, https://law.counselstack.com/opinion/amedisys-inc-v-jp-morgan-chase-manhattan-bank-in-re-national-century-ohsb-2005.